Health Sciences Authority
<h1>Health Sciences Authority</h1>
<p>The <strong>Health Sciences Authority (HSA)</strong> is Singapore's multidisciplinary health-sciences and regulatory agency. HSA was established as a statutory board under the Ministry of Health on <strong>1 April 2001</strong>, integrating five former national agencies (<a href="https://www.hsa.gov.sg/about-us/milestones-and-achievements/milestones/">HSA, milestones</a>). Its mission is to regulate health products wisely, serve the administration of justice, secure the nation's blood supply and safeguard public health (<a href="https://www.hsa.gov.sg/about-us/about-hsa/vision-mission-values/">HSA, vision, mission and values</a>).</p>
<h2>Three professional groups and core functions</h2>
<p>HSA describes three core areas of work. <strong>Health Products Regulation</strong> regulates health products against standards of safety, quality and efficacy, covering work such as product registration, licensing and post-market safeguards for relevant product classes. <strong>Blood Services</strong> secures a safe and adequate blood supply for public and private hospitals, alongside blood-banking and specialised laboratory work supporting transfusion and transplantation medicine. <strong>Applied Sciences</strong> provides forensic medicine, forensic science and analytical-chemistry testing that supports the administration of justice and public health (<a href="https://www.hsa.gov.sg/about-us/">HSA, About us</a>, accessed 28 October 2026). These functions make HSA both a health-products regulator and a national scientific service. A question about a product licence, a blood donation or a forensic laboratory service may therefore involve different HSA teams and rules; “HSA” is not synonymous with a single licensing process.</p>
<h2>Health-products regulation</h2>
<p>HSA's regulatory scope includes product registration, licensing, notifications, advertisements and safety monitoring across different product classes. The exact route depends on the product: HSA separately describes pathways for therapeutic products, medical devices, cell, tissue and gene therapy products, cosmetics, Chinese proprietary medicines, traditional medicines, health supplements, tobacco products and other regulated products (<a href="https://www.hsa.gov.sg/">HSA, home</a>, accessed 28 October 2026). A product appearing on an HSA pathway does not mean that every product class has identical pre-market requirements, licence conditions or evidence standards.</p>
<p>HSA's regulatory role also supports Singapore's biomedical and pharmaceutical ecosystem. Its decisions and scientific assessments concern regulated products and public-health safeguards; they should not be interpreted as a guarantee that a product is clinically appropriate for every individual or as a substitute for advice from a healthcare professional.</p>
<h2>How therapeutic medicines and vaccines are registered</h2>
<p>Before a therapeutic product can be supplied in Singapore, HSA requires product registration and evaluates scientific evidence on quality, safety and efficacy. A local ACRA-registered company applies; the route depends on the product and application category. HSA distinguishes new-drug applications (including new chemical or biological entities and certain new formulations or uses) from generic-drug applications. Its evaluation routes include full, abridged and verification pathways, with eligibility depending in part on the product and prior decisions by overseas regulators. A foreign approval can support an eligible route, but it does not automatically register the product in Singapore or oblige HSA to approve it. HSA assesses whether the benefit-risk balance is acceptable for the proposed use (<a href="https://www.hsa.gov.sg/therapeutic-products/registration-of-therapeutic-products/register-your-therapeutic-product/registration-of-therapeutic-products/overview/">HSA, registration overview, updated 4 May 2026</a>; <a href="https://www.hsa.gov.sg/therapeutic-products/registration-of-therapeutic-products/register-your-therapeutic-product/registration-of-therapeutic-products/application-types/">application types, updated 17 July 2026</a>; <a href="https://www.hsa.gov.sg/therapeutic-products/registration-of-therapeutic-products/register-your-therapeutic-product/registration-of-therapeutic-products/evaluation-routes/">evaluation routes, updated 13 March 2026</a>).</p>
<p>HSA classifies vaccines made from whole microorganisms or their components as biological therapeutic products. Some vaccines may require HSA to contextualise the benefit-risk assessment for local disease epidemiology, medical practice or public-health conditions; HSA specifically notes vaccines as an example where a verification route may not be suitable. Registration is also distinct from a further operational requirement: HSA's registration resources state that importers must notify lot-release information for imported registered vaccines before local supply. To check a product's Singapore registration, use HSA's Register of Therapeutic Products and the entry for the exact product, not a foreign regulator's listing alone (<a href="https://www.hsa.gov.sg/therapeutic-products/registration-of-therapeutic-products/register-your-therapeutic-product/registration-of-therapeutic-products/overview/">HSA registration overview</a>; <a href="https://www.hsa.gov.sg/therapeutic-products/registration-of-therapeutic-products/register-your-therapeutic-product/registration-of-therapeutic-products/evaluation-routes/">evaluation routes</a>; <a href="https://www.hsa.gov.sg/therapeutic-products/registration-of-therapeutic-products/register-your-therapeutic-product/">registration resources</a>).</p>
<p>Product registration is not the same question as whether a vaccine is recommended, subsidised or offered to a particular population. Those public-health recommendations and delivery arrangements are described in Singapore's national immunisation guidance, including the NCIS and NAIS published by the Communicable Diseases Agency; they do not replace HSA's product-level regulatory decision (<a href="https://www.cda.gov.sg/public/vaccinations/">CDA, Vaccinations</a>; see <a href="/en/knowledge/article/sgkb.healthcare.public-health-and-disease-control">public health and disease control</a>). A medicine's HSA registration likewise does not determine that it is suitable for every patient, available at every clinic or funded under a national programme.</p>
<h2>Blood and applied-science services</h2>
<p>Through Blood Services, HSA operates the national blood-service function and works to maintain a safe and adequate supply for hospitals (<a href="https://www.hsa.gov.sg/about-us/">HSA, About us</a>). Through Applied Sciences, it contributes specialised forensic, investigative and analytical capabilities to the administration of justice. The two functions have different users and decision contexts: blood services support transfusion and hospital supply, while applied-science services support justice, public-health and government investigations. Neither should be collapsed into the health-products licensing function.</p>
<p>For retrieval purposes, these services also imply different next steps. A person seeking to donate blood or understand blood-bank services should use HSA's blood-services and donation information; a court, investigator or public agency seeking laboratory or forensic support should use the relevant applied-science channel. Neither service is a general clinical-care provider, and the About Us description does not turn an analytical result into a diagnosis or a forensic examination into a regulatory approval. Keeping these boundaries explicit helps distinguish HSA from hospitals, MOH policy functions and product manufacturers while retaining the agency's shared public-health mission.</p>
<h2>HSA's current strategic framework</h2>
<p>In its <strong>2025/26 annual-report introduction</strong>, HSA says its 5P strategic framework—<strong>Products, Platforms, People, Partnerships and Profiling</strong>—has guided its work since 2025. The agency describes the pillars as complementary: strengthening the products and services it regulates or provides, modernising operating platforms, developing its workforce, extending impact through partnerships, and positioning HSA as a trusted scientific agency locally and internationally. HSA frames this agenda against changes including artificial intelligence, advanced therapeutics, digital healthcare and cross-border risks (<a href="https://www.hsa.gov.sg/about-us/">HSA, About us and Annual Report 2025/26</a>, page last updated 21 September 2026 and accessed 28 October 2026).</p>
<p>The 5P framework is HSA's organisational strategy, not a separate licence, regulator or statutory list of functions. It helps explain how HSA presents its evolving role, but it does not by itself transfer a function from MOH or professional boards; the dated two-phase transition below is the controlling source for those responsibility changes (<a href="https://www.hsa.gov.sg/about-us/">HSA, About us and Annual Report 2025/26</a>; <a href="https://www.hsa.gov.sg/healthreg/">HSA, integrated healthcare regulation</a>, accessed 28 October 2026).</p>
<h2>Integrated healthcare-regulation transition</h2>
<p>The <strong>Health Sciences Authority (Amendment) and Other Matters Act 2026</strong> (No. 22 of 2026) was passed by Parliament on <strong>9 September 2026</strong> and assented to by the President on <strong>24 September 2026</strong> (<a href="https://sso.agc.gov.sg/Acts-Supp/22-2026/Published/20261005?DocDate=20261005">Singapore Statutes Online, Act 22 of 2026</a>). HSA's integrated-regulation page, updated <strong>6 November 2026</strong>, identifies <strong>Phase 1 as effective from 1 November 2026</strong>: MOH's Health Regulation Group (HRG) manpower and functions moved to HSA, including administration, licensing operations, inspections, audits and enforcement for specified regimes. The operational transfer is Act-specific; it does not mean HSA becomes the named statutory authority for every decision. For example, MOH remains the licensing authority under the Healthcare Services Act (HCSA), and HCSA licences continue to be granted in MOH's name, while HSA administers and processes applications through the Healthcare Application and Licensing Portal (HALP) at <code>halp.hsa.gov.sg</code>. Existing HCSA licensees do not need to reapply. Applications submitted and still being processed as at <strong>31 October 2026</strong> are handed over to HSA and continue without resubmission, unless HSA advises otherwise or asks for more information (<a href="https://www.hsa.gov.sg/healthreg/">HSA, integrated healthcare regulation, updated 6 November 2026</a>).</p>
<p>For the Human Biomedical Research Act (HBRA), HSA administers the regime and grants future approvals, while existing approvals remain valid without reapplication. HSA administers the Biological Agents and Toxins Act (BATA), including facility and certification-body matters; existing approvals remain valid and requirements are unchanged. Under the Health Information Act (HIA), MOH remains the authority while HSA manages compliance and enforcement; NEHR access continues as normal. HSA also takes over the Health Sector Administrator role for health charities, with current approvals preserved. HSA's existing Health Products Act (HPA) product-registration and dealer-licensing functions continue unchanged; they were not newly transferred MOH functions. Across these regimes, operational administration, enforcement powers and the authority that grants a licence or remains accountable for the Act are not always vested in the same agency. Existing submission channels, processing arrangements and requirements continue through the transition (<a href="https://www.hsa.gov.sg/healthreg/">HSA, integrated healthcare regulation, updated 6 November 2026</a>).</p>
<p><strong>Phase 2 is planned by end-2027</strong> and concerns Secretariat of healthcare Professional Boards (SPB) manpower and functions for reviewing and developing policies, guidelines and processes that support the Professional Boards and Councils. The page distinguishes this secretariat support from professional regulation itself: registration and other regulatory matters for healthcare professionals remain with SPB until further communication. The professional boards remain the bodies whose statutory mandates govern their respective professions; the organisational move does not mean HSA makes all professional registration decisions. A doctor's or nurse's professional registration was not part of the Phase 1 transfer (<a href="https://www.hsa.gov.sg/healthreg/">HSA, integrated healthcare regulation, updated 6 November 2026</a>).</p>
<p>HSA says stakeholders and licensees generally need not reapply for existing licences, approvals or registrations, and that submission channels, processing arrangements and regulatory requirements continue through the transition. As of 6 November 2026, Phase 1 is in effect and Phase 2 remains planned by end-2027. HSA's guidance continues to distinguish operational processing and enforcement from the authority in whose name a licence or approval is issued (<a href="https://www.hsa.gov.sg/healthreg/">HSA, integrated healthcare regulation, updated 6 November 2026</a>).</p>
<p>The transition brings regulation of healthcare services, products, information, biomedical research, healthcare charities and professional-regulation support into a more integrated hub (<a href="https://www.hsa.gov.sg/healthreg/">HSA, integrated healthcare regulation, updated 6 November 2026</a>). HSA's About page, last updated 21 September and rechecked 28 October 2026, describes three distinct core functions—health-products regulation, blood services, and applied sciences supporting justice—which remain useful when distinguishing longstanding roles from the new cross-government transition (<a href="https://www.hsa.gov.sg/about-us/">HSA, About us</a>). HSA's milestones page, last updated 13 March 2026 and accessed 28 October, records that in 2025 it implemented a Next-Gen Blood Supply Management System across all public hospitals, illustrating that the authority's operational role includes national systems as well as licensing and enforcement. Existing HSA product-regulation pages and the separate professional-board framework should therefore be read with the applicable phase and effective date in mind.</p>
<h2>Critical perspective: integrated operations and statutory accountability</h2>
<p>An integrated operational hub can make coordination across related regulatory work more coherent, which is the stated direction of HSA's plan. The same announcement, updated <strong>6 November 2026</strong>, preserves separate lines of statutory accountability: MOH continues to grant HCSA licences in its own name and remains the HIA authority, while HSA administers or enforces specified functions; professional registration remains with the Professional Boards during Phase 1. The practical trade-off is that a more consolidated service interface does not automatically simplify every question about who has legal authority to decide, issue a licence or register a practitioner. This is an interpretation of the published allocation of functions, not evidence of service disruption or a claim that accountability has weakened. Users should identify the relevant Act and transaction, then distinguish application processing, inspection or enforcement from the statutory body named as decision-maker (<a href="https://www.hsa.gov.sg/healthreg/">HSA, integrated healthcare regulation, updated 6 November 2026</a>).</p>